Apoquel costs roughly $70 to $90 for a 30-day supply, depending on the tablet strength, making it one of the pricier ongoing medications dog owners face. That price reflects a combination of factors: it’s a targeted, patented drug made by a single manufacturer, it requires complex chemistry to produce, and there’s no generic version to drive competition. Here’s a closer look at what’s behind the price tag.
It’s a Precision Drug, Not a Blunt Tool
The most basic reason Apoquel costs more than older allergy treatments like steroids is that it does something fundamentally different. Steroids suppress the immune system broadly, which controls itching but comes with a long list of side effects. Apoquel (oclacitinib) is a JAK inhibitor, a class of drug that selectively blocks a specific enzyme called JAK1. That enzyme is the one responsible for transmitting the itch and inflammation signals triggered by allergic reactions in dogs.
By targeting JAK1 specifically, Apoquel shuts down the cytokines that drive allergic itch (particularly one called IL-31) while mostly leaving other immune functions alone. In lab testing, oclacitinib inhibited JAK1 at a concentration roughly 10 times lower than what was needed to affect other JAK family members, and it had no meaningful effect on 38 other kinase enzymes tested. That precision is what makes it effective with fewer side effects than steroids, but developing and manufacturing a drug with that kind of selectivity costs significantly more than producing a generic corticosteroid.
Manufacturing Is Genuinely Complex
Oclacitinib isn’t a simple molecule to produce. Its chemical structure includes two main components: a modified pyrimidine ring system and a piperidine fragment. The piperidine portion contains two asymmetric centers, meaning the molecule has to be built in a very specific three-dimensional arrangement. Getting that arrangement right at large scale (kilogram quantities for commercial production) has been described in pharmaceutical chemistry literature as a significant synthesis challenge. Every step that adds complexity to manufacturing adds cost, and those costs get passed along in the retail price.
Zoetis Has No Generic Competition
Apoquel is manufactured exclusively by Zoetis, the largest animal health company in the world. There is no generic version of oclacitinib available, which means Zoetis sets the price without competitive pressure from cheaper alternatives. This is the same dynamic that keeps any patented drug expensive: one company invested in the research, clinical trials, and regulatory approval process, and they hold the exclusive right to sell it.
Zoetis has consistently highlighted Apoquel as a key growth driver in its financial reporting. In their most recent quarterly earnings, the company cited its “key dermatology portfolio including Apoquel” as a primary contributor to companion animal revenue growth. When a single product is that important to a company’s bottom line, there’s little incentive to lower the price, especially without competition.
What You’ll Actually Pay
Current average retail prices for a 30-day supply of Apoquel chewable tablets, based on GoodRx data:
- 3.6 mg (30 tablets): about $89.52
- 5.4 mg (30 tablets): about $89.73
- 16 mg (30 tablets): about $70.69
For many dogs, especially those with chronic allergies, Apoquel is a daily medication taken year-round. That puts the annual cost somewhere between $850 and $1,100 depending on your dog’s dose. And because larger dogs may need higher or combined doses, the yearly expense can climb further.
For context, a course of prednisone for allergies might cost a few dollars a month. But steroids aren’t a great long-term option for most dogs because of side effects like increased thirst, weight gain, and immune suppression. Apoquel fills the gap between “cheap but rough on the body” and “effective and well-tolerated,” and that gap is where the pricing power lives.
How It Compares to Human JAK Inhibitors
One useful way to put Apoquel’s cost in perspective: it’s actually far cheaper than the human equivalents. A recent pricing comparison published in Proceedings of Baylor University Medical Center found that oclacitinib costs about $3.10 per pound of body weight per month for veterinary use. Human JAK inhibitors like abrocitinib and upadacitinib run $193 to $220 per pound per month. So while Apoquel feels expensive relative to other pet medications, the same class of drug costs roughly 60 to 70 times more on the human side.
Ways to Reduce the Cost
Zoetis runs a rewards program called Zoetis Petcare Rewards that offers points on Apoquel purchases. You earn points based on the number of tablets purchased, and those points convert to credit you can use toward future vet visits at a rate of 10 points per dollar. A 30-tablet purchase earns 70 points ($7 back at the base tier), while larger quantities earn more. The program has tiered multipliers (Bronze, Silver, Gold) that increase your points by 1.25x to 1.5x as you buy more over time. It’s not dramatic savings, but for a medication you’re buying every month, it adds up. Zoetis advertises up to $90 in rewards annually.
Beyond the manufacturer’s program, buying in larger quantities (90 or 180 tablets at a time) typically brings the per-pill cost down. Some online veterinary pharmacies offer lower prices than brick-and-mortar clinics, though you’ll need a prescription from your vet either way. Pet insurance that covers prescription medications can also offset the cost significantly if your dog is on Apoquel long-term, though you’d want to confirm allergy medication is covered before enrolling, since some plans exclude it.
Cytopoint, an injectable alternative also made by Zoetis, works through a completely different mechanism (it’s an antibody that neutralizes the itch signal directly) and is given every 4 to 8 weeks at the vet’s office rather than daily at home. For some dogs, it ends up being comparable in cost or even cheaper depending on the dog’s size and how long each injection lasts. It’s worth discussing with your vet if the monthly Apoquel bill is unsustainable.